Model expected to include digital intake, clinician evaluation, prescription routing, monitoring coordination, and subscription-based patient supportVANCOUVER, BC / ACCESS Newswire / August 7, 2026 / Fifty 1 Labs, Inc. (OTCID:FITY) today provided an overview of its planned U.S. - focused telehealth peptide services platform. The Company intends to develop a patient-facing service model that complements its peptide science and commercialization strategy while remaining separate from investigational clinical-development programs. Fifty 1 Labs anticipates that the telehealth service line may generate revenue through monthly membership fees, virtual visit fees, care-management services, laboratory and monitoring coordination, patient-support services, and pharmacy-related service arrangements where legally permissible. The timing and launch of the telehealth service line remain subject to regulatory review, clinician contracting, pharmacy integration, technology development, insurance, state-by-state legal analysis, and financing. About Fifty 1 Labs, Inc.Fifty 1 Labs, Inc. is a biotechnology and health-sciences company focused on peptide products, peptide sciences, AI-enabled discovery, musculoskeletal health, sports recovery, and planned U.S. telehealth peptide services.